Immutep Limited logo
Immutep Limited IMMP
$ 4.65 0.21%
report update icon

Quarterly report 2025-Q4
added 09-22-2026

Immutep Limited Financial Ratios 2025-2011 | IMMP

Annual Financial Ratios Immutep Limited

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-48.3 -52.0 -39.1 -48.0 -65.3 -9.3 -3.2 -3.8 -5.1 -1.5 -2.7 -4.5 -10.0 -9.3 -

P/S

287.5 283.5 300.3 228.6 491.8 7.6 7.8 6.6 - 526.3 - - - 121.6 -

EPS

-0.0 -0.0 -0.0 -0.0 -5.0 -3.4 -0.6 -0.5 -0.4 -2.8 - - - - -

EV (Enterprise Value)

2.92 B 2.07 B 1.45 B 1.47 B 1.9 B 113 M 57.7 M 38.3 M 32.1 M 56.2 M 71.4 M 48.6 M 119 M 144 M 2.54 M

EBITDA per Share

- - - - - - - - -0.403 -2.65 -1.96 -1.17 -1.5 -1.69 -

EV/EBITDA

- - - - - -2.8 -2.3 -5.2 -3.5 -0.9 -1.9 -2.2 -5.7 -5.9 -

PEG

- - - - 1.57 0.13 -0.22 -0.8 0.06 -0.04 -0.03 0.2 0.78 0.19 -

P/B

20.7 11.7 11.4 16.4 26.6 3.8 2.4 1.4 1.8 2.6 3.5 2.7 5.2 5.0 -

P/CF

-47.9 -63.8 -44.2 -51.1 -110.6 -11.6 -3.8 -6.2 -4.2 -6.2 -8.3 -3.2 -7.0 -7.1 -

ROE %

-42.77 -22.54 -29.23 -34.24 - -40.45 -75.22 -38.02 -35.30 -175.59 -130.22 -59.06 -52.06 -53.67 -

ROA %

-39.13 -21.19 -27.06 -31.53 -36.45 -28.90 -45.25 -27.12 -26.79 -145.73 -103.77 -52.58 -46.40 -47.92 -

ROCE %

- - - - - - - - -29.25 -150.28 -55.18 -63.92 -59.69 -56.86 -

Current Ratio

11.8 16.7 13.4 12.6 9.4 3.5 2.5 3.5 6.0 14.7 1.8 8.9 8.9 9.2 -

DSO

- - - - - - - - - 351.3 - - - 190.5 -

All numbers in AUD currency

Quarterly Financial Ratios Immutep Limited

2025-Q4 2024-Q4 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Current Ratio

13.4 12.6 9.4 - - - - - - 9.4 - - - 3.5 - - - 2.5 - - - 3.5 - - - 4.2 - - - 5.9 - - - - - - - - - - - - - - - - - - - - -

All numbers in AUD currency

Multiples are an important financial analysis tool for the company Immutep Limited, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Spruce Biosciences Spruce Biosciences
SPRB
$ 48.58 2.77 % $ 37.2 M usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
$ 1.21 0.83 % $ 67.8 M usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 18.22 0.7 % $ 1.82 B usaUSA
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 48.32 1.19 % $ 5.54 B usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
$ 26.0 0.46 % $ 1.54 B usaUSA
Sutro Biopharma Sutro Biopharma
STRO
$ 16.11 0.06 % $ 137 M usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 6.82 4.28 % $ 475 M usaUSA
Supernus Pharmaceuticals Supernus Pharmaceuticals
SUPN
$ 43.04 4.55 % $ 2.43 B usaUSA
Savara Savara
SVRA
$ 5.16 1.57 % $ 1.15 B usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 3.01 7.12 % $ 2.05 M chinaChina
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 18.19 0.21 % $ 28.7 B japanJapan
Protara Therapeutics Protara Therapeutics
TARA
$ 3.05 0.31 % $ 131 M usaUSA
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
$ 78.61 2.5 % $ 3.28 B usaUSA
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.47 0.12 % $ 11.3 B usaUSA
Tenax Therapeutics Tenax Therapeutics
TENX
$ 1.89 2.72 % $ 74.1 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 39.6 0.05 % $ 45.3 B israelIsrael
TG Therapeutics TG Therapeutics
TGTX
$ 55.78 0.07 % $ 8.05 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals Holding Corp.
TNXP
$ 9.74 0.93 % $ 82.9 M usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 14.32 0.38 % $ 1.93 B usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 4.87 0.1 % $ 1.56 B usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
$ 40.63 0.44 % $ 1.95 B israelIsrael
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 541.89 12.55 % $ 24 B usaUSA
Vericel Corporation Vericel Corporation
VCEL
$ 40.14 0.92 % $ 2.02 B usaUSA
Veracyte Veracyte
VCYT
$ 46.04 0.89 % $ 3.62 B usaUSA
Vir Biotechnology Vir Biotechnology
VIR
$ 11.18 4.98 % $ 1.55 B usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
$ 32.6 2.48 % $ 3.67 B usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
$ 4.91 0.8 % $ 289 M usaUSA
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 4.8 7.51 % $ 51.1 M usaUSA
Viridian Therapeutics Viridian Therapeutics
VRDN
$ 20.59 2.98 % $ 2.1 B usaUSA
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 522.81 0.07 % $ 134 B usaUSA
Verastem Verastem
VSTM
$ 8.05 1.64 % $ 558 M usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
$ 0.31 3.29 % $ 11.8 M usaUSA
vTv Therapeutics vTv Therapeutics
VTVT
$ 30.84 2.8 % $ 122 M usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 2.68 1.52 % $ 157 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
$ 3.7 1.65 % $ 624 M singaporeSingapore
Xenetic Biosciences Xenetic Biosciences
XBIO
$ 2.32 2.65 % $ 3.95 M usaUSA
XBiotech XBiotech
XBIT
$ 2.19 0.46 % $ 66.8 M usaUSA
Exicure Exicure
XCUR
$ 1.19 4.38 % $ 7.49 M usaUSA
Xenon Pharmaceuticals Xenon Pharmaceuticals
XENE
$ 37.19 0.24 % $ 2.95 B canadaCanada
Xeris Pharmaceuticals Xeris Pharmaceuticals
XERS
$ 9.56 1.53 % $ 1.53 B usaUSA
X4 Pharmaceuticals X4 Pharmaceuticals
XFOR
$ 2.9 0.17 % $ 123 M usaUSA
Xencor Xencor
XNCR
$ 24.95 0.86 % $ 1.85 B usaUSA
22nd Century Group 22nd Century Group
XXII
$ 0.84 4.78 % $ 155 K usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
$ 26.34 1.58 % $ 28.9 B chinaChina
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
$ 2.77 2.03 % $ 199 M usaUSA
Zoetis Zoetis
ZTS
$ 69.83 0.07 % $ 31 B usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA